{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:00:47Z","timestamp":1790521247537,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R2). Moreover, mechanisms of resistance to R2 in FL remain unclear, with increased protumoral macrophages suspected as a major contributory culprit to this phenomenon. This retrospective study analyzed the outcome of patients with advanced-stage FL grade 1 to 3A who relapsed or progressed after frontline R2. A multiplex immunofluorescence macrophage panel, including CD47, CD14, CD68, CD115 (also known as colony-stimulating factor 1 receptor [CSF1R]), CD163, CD172a (also known as signal regulatory protein \u03b1 [SIRP\u03b1]), and CD274 (also known as programmed cell death-ligand 1 [PDL1]), was used to stain tissue biopsy specimens collected before initiation of R2 and at the time of progression. Among 156 patients with advanced-stage FL treated with frontline R2, 33 (21%) relapsed or progressed and required second-line therapy, after a median of 33 months (range, 1-122 months). Second-line therapy was chemoimmunotherapy in 16 (48%) patients and other therapy in 17 (52%). The overall response rate was 78%, and complete response rate was 72%. Median progression-free survival was significantly longer in patients who received chemoimmunotherapy compared with other therapy (99 vs 25 months; P = .004). Three macrophage populations were significantly increased in tissue samples collected at progression compared with before frontline treatment: CD68+CD115+ (P = .02), CD68+CD115+CD172a+ (P = .02), and CD68+CD163+CD172a+ (P = .01). Chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2. Therapies targeting specific macrophage populations may yield novel approaches for improving outcomes with frontline R2.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007104","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:17:26Z","timestamp":1648775846000},"page":"3286-3293","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["SIRP\u03b1+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-2096","authenticated-orcid":false,"given":"Mario L.","family":"Marques-Piubelli","sequence":"first","affiliation":[{"name":"1Department of Translational Molecular Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa Solis","family":"Soto","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Gallardo","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Gouni","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Noorani","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8697","authenticated-orcid":false,"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian R.","family":"Gunther","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[{"name":"5Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"1Department of Translational Molecular Pathology,"},{"name":"3Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"issue":"4","key":"2022060215235034500_B1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood."},{"issue":"12","key":"2022060215235034500_B2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"issue":"11","key":"2022060215235034500_B3","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol."},{"issue":"10","key":"2022060215235034500_B4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"key":"2022060215235034500_B5","author":"National Comprehensive Cancer Network"},{"issue":"8","key":"2022060215235034500_B6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2020007994","article-title":"Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood."},{"key":"2022060215235034500_B7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","article-title":"Mechanisms of lenalidomide sensitivity and resistance","volume":"91","author":"Martinez-H\u00f8yer","year":"2020","journal-title":"Exp Hematol."},{"issue":"2","key":"2022060215235034500_B8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol."},{"issue":"10","key":"2022060215235034500_B9","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J Clin Invest."},{"issue":"21","key":"2022060215235034500_B10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med."},{"issue":"15","key":"2022060215235034500_B11","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"20","key":"2022060215235034500_B12","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1182\/bloodadvances.2021005722","article-title":"Follicular lymphoma and macrophages: impact of approved and novel therapies","volume":"5","author":"Gouni","year":"2021","journal-title":"Blood Adv."},{"issue":"4","key":"2022060215235034500_B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun (Lond)."},{"issue":"3","key":"2022060215235034500_B14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022060215235034500_B15","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-C\u00e9ligny","year":"1998","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022060215235034500_B16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"issue":"11","key":"2022060215235034500_B17","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/bloodadvances.2018017681","article-title":"Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL","volume":"2","author":"Pinnix","year":"2018","journal-title":"Blood Adv."},{"issue":"27","key":"2022060215235034500_B18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022060215235034500_B19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica."},{"issue":"10","key":"2022060215235034500_B20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-019-0246-0","article-title":"SIRP\u03b1 expression delineates subsets of intratumoral monocyte\/macrophages with different functional and prognostic impact in follicular lymphoma","volume":"9","author":"Chen","year":"2019","journal-title":"Blood Cancer J."},{"issue":"34","key":"2022060215235034500_B21","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022060215235034500_B22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol."},{"issue":"9","key":"2022060215235034500_B23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","article-title":"The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma","volume":"35","author":"Valero","year":"2021","journal-title":"Leukemia."},{"issue":"22","key":"2022060215235034500_B24","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022060215235034500_B25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/hematology.2020000156","article-title":"How do I sequence therapy for follicular lymphoma?","volume":"2020","author":"Salles","year":"2020","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"1","key":"2022060215235034500_B26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2018.1.189","article-title":"Sequencing of therapies in relapsed follicular lymphoma","volume":"2018","author":"Nastoupil","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"5","key":"2022060215235034500_B27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clml.2018.12.019","article-title":"Assessing the effectiveness of treatment sequences for older patients with high-risk follicular lymphoma with a multistate model","volume":"19","author":"\u00c7a\u011flayan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"7","key":"2022060215235034500_B28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"key":"2022060215235034500_B29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood-2019-125315","article-title":"Dynamics of the cutaneous T cell lymphoma microenvironment in patients treated with pembrolizumab revealed by highly multiplexed tissue imaging","volume":"134","author":"Schuerch","year":"2019","journal-title":"Blood."},{"issue":"pt 11","key":"2022060215235034500_B30","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1242\/jcs.108.11.3419","article-title":"In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)","volume":"108","author":"Reinhold","year":"1995","journal-title":"J Cell Sci."},{"issue":"5473","key":"2022060215235034500_B31","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science."},{"issue":"18","key":"2022060215235034500_B32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"2022060215235034500_B33","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2022060215235034500_B34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2020-135941","article-title":"ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022060215235034500_B35","first-page":"179","article-title":"Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment","volume":"3","author":"Kaur","year":"2020","journal-title":"Antib Ther."},{"issue":"10","key":"2022060215235034500_B36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med."},{"issue":"4","key":"2022060215235034500_B37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol."},{"issue":"1","key":"2022060215235034500_B38","first-page":"61","article-title":"Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice","volume":"63","author":"Mantovani","year":"1979","journal-title":"J Natl Cancer Inst."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3286\/1899936\/advancesadv2022007104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3286\/1899936\/advancesadv2022007104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:27:04Z","timestamp":1654183624000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3286\/484511\/SIRP-macrophages-are-increased-in-patients-with-FL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007104","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}